Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option

Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option

The European Medicines Agency (EMA) has accepted Teva Pharmaceuticals and Medincell's marketing authorization application for their once-monthly olanzapine long-acting injectable (LAI) for the treatment of schizophrenia in adults. This regulatory milestone signifies a potential new adherence-focused treatment option for patients in Europe.

Key Takeaways

• The EMA accepted Teva and Medincell's marketing authorization application for olanzapine LAI (TEV-749), a once-every-four-weeks subcutaneous injection for adults with schizophrenia.
• The submission targets the persistent adherence gap in schizophrenia treatment, where daily oral regimens suffer from high discontinuation rates.
• An EMA decision is expected within the standard 210-day review timeline, potentially positioning the therapy for European launch in 2027.
• Teva simultaneously pursues an FDA filing for TEV-749, creating a dual-regulatory catalyst over the next 12–18 months.
• The product leverages Medincell's proprietary BEPO sustained-release technology, differentiating it from existing LAI antipsychotics on the market.

EMA Accepts Teva and Medincell's Olanzapine LAI Application

The European Medicines Agency has formally accepted the marketing authorization application for Teva and Medincell's once-monthly olanzapine long-acting injectable, designated TEV-749, according to a Stock Titan report dated May 21, 2026. The application covers the treatment of schizophrenia in adults using a subcutaneous formulation administered once every four weeks.

EMA acceptance of an MAA triggers the start of the Committee for Medicinal Products for Human Use (CHMP) review clock — a pivotal regulatory checkpoint that moves the program from clinical development into the commercial pathway. The standard CHMP evaluation runs approximately 210 days, with potential clock-stops if the committee issues questions to the sponsors. Teva has not disclosed whether it received accelerated assessment designation, which would shorten the review window.

TEV-749 pairs olanzapine — one of the most widely prescribed atypical antipsychotics globally — with Medincell's BEPO technology, a biodegradable in-situ forming depot designed to release drug steadily over a 28-day period. Teva submitted its New Drug Application to the FDA in late 2025 for the same indication, making TEV-749 a dual-front regulatory story for investors tracking both agencies.

Why Long-Acting Injectables Matter in Schizophrenia

Non-adherence remains the single greatest obstacle in schizophrenia management. Studies consistently show that roughly 40–60% of patients discontinue oral antipsychotics within the first year of treatment, leading to relapse, hospitalization, and long-term functional decline. Long-acting injectables were designed to solve exactly this problem — replacing daily pill-taking with clinician-administered or self-administered injections at defined intervals.

Yet the LAI market for schizophrenia remains underpenetrated relative to its clinical rationale. Uptake has been constrained by formulation limitations: first-generation LAIs required painful intramuscular depot injections, and even second-generation options like paliperidone palmitate (Invega Sustenna/Trinza) involve loading-dose complexities and injection-site reactions. A once-monthly subcutaneous olanzapine injection could lower the barrier considerably. Olanzapine itself has a well-characterized efficacy and safety profile spanning decades of clinical use; the innovation here is delivery, not molecule.

Medincell's BEPO platform, which forms an in-situ biodegradable depot upon subcutaneous injection, could offer pharmacokinetic advantages over competing LAI technologies — specifically a smoother plasma concentration curve without the burst-release effect seen with some microsphere-based formulations. If the clinical data support this profile, TEV-749 could capture prescribers who have been hesitant to switch patients from oral olanzapine to existing LAIs.

How Does TEV-749 Fit the Competitive Landscape?

The European schizophrenia LAI market is anchored by Janssen's paliperidone palmitate franchise (Invega Sustenna and the three-month formulation Trinza), which generated over $4 billion globally in recent years. Alkermes' Aristada (aripiprazole lauroxil) and Otsuka's Abilify Maintena (aripiprazole monohydrate) hold smaller but meaningful shares. None of these products delivers olanzapine in a long-acting format — a gap TEV-749 is explicitly designed to fill.

Oral olanzapine remains one of the most prescribed antipsychotics worldwide, though its use has been tempered by metabolic side-effect concerns — weight gain, dyslipidemia, and glucose dysregulation. An LAI formulation does not eliminate these risks, but it does ensure consistent drug exposure and removes the peaks and troughs associated with intermittent oral dosing, which some clinicians believe exacerbates metabolic variability.

For Teva, TEV-749 represents a strategic play to reinvigorate its psychiatry portfolio and capitalize on its existing commercial infrastructure for CNS products. For Medincell, European approval would validate the BEPO platform beyond its earlier deals and strengthen the French biotech's negotiating position in future partnership discussions. The companies have not disclosed specific commercial terms of their arrangement.

What Are the Next Regulatory Steps?

Following MAA acceptance, the CHMP will conduct its scientific assessment and is expected to adopt an opinion within approximately 12 months. If positive, the European Commission typically issues a binding marketing authorization decision within 67 days of the CHMP opinion, granting access to all EU member states plus the European Economic Area.

Investors should watch for three specific milestones: first, any public disclosure of CHMP questions or clock-stops, which would signal regulatory scrutiny; second, the FDA's response to Teva's parallel NDA filing, where a Prescription Drug User Fee Act (PDUFA) date would set a clear timeline; and third, any updates on manufacturing readiness, since LAI formulations require specialized aseptic fill-finish capacity.

Pricing and reimbursement negotiations across European markets will shape the commercial upside. Germany's AMNOG process, France's HAS assessment, and the UK's NICE evaluation each carry distinct timelines and evidence requirements that could delay launch even after EMA approval.

What Does This Mean for Teva's Pipeline Valuation?

Teva's stock has traded at a significant discount to large-cap pharma peers, weighed down by litigation overhang, debt from the Allergan generics acquisition, and concerns about its branded pipeline's ability to offset generic erosion. TEV-749 alone is unlikely to close that valuation gap, but it contributes to a broader narrative of pipeline diversification — alongside Teva's biosimilar portfolio and its Austedo franchise for tardive dyskinesia and Huntington's disease.

Analysts modeling TEV-749 revenue should assume a gradual European launch trajectory. LAI adoption typically builds slowly as prescribers gain comfort with injection protocols and payers establish reimbursement pathways. Peak sales estimates for a once-monthly olanzapine LAI in Europe range from $200 million to $600 million depending on pricing assumptions and the degree to which it cannibalizes oral olanzapine prescriptions versus expanding the overall treated population.

The key risk remains clinical differentiation. If TEV-749's pivotal trials demonstrated clear superiority over oral olanzapine in adherence-driven outcomes — not just non-inferiority — the product would command stronger formulary positioning. Investors should scrutinize the full data package when it becomes available through regulatory summaries or medical conference presentations.

Frequently Asked Questions

Related profiles

• olanzapine
• Teva